Solid phase immunoradiometric assay for CA125 antigen levels in blood using monoclonal antibodies

  • Anjani N. Rundekar
  • P. C. Vrinda
  • N. Sivaprasad


We have developed a simple one step ‘sandwich’ immunoradiometric assay for CA125 using monoclonal antibodies directed against two different epitopes of the antigen. The detection antibody was radiolabeled with I-125 and the selected capture antibody was chemically coupled to magnetizable cellulose to form immobilized solid support. In the developed inclusive assay procedure, 200 μL of standard or sample was incubated with 100 μL of radiolabeled and capture antibody suspension for 18 h at room temperature with shaking. At the end of the incubation, the sandwich complex attached to solid phase is separated and counted for associated radioactivity. The analytical sensitivity for the developed assay procedure was observed to be 3.0 U/mL with an assay range up to 500 U/mL of CA125. The developed assay displayed acceptable precision; expressed in terms of percentage Coefficient of Variation (CV) estimated by repeated analyses of the quality control samples. Intra-assay CV was observed to be less than 5% whereas inter-assay CV was also less than 6%. The analytical recovery of the developed assay observed to be in the range of 88–107%. The clinical samples analyzed by the developed procedure showed a good correlation with that of a commercial kit (r = 0.99; y = 1.0052x − 38.942).


Immunoradiometric CA125 antigen Tumor marker Ovarian carcinoma 



Authors thank Dr. A. K. Kohli, Chief Executive, BRIT for his support. The authors are also thankful to Shri. Harish Chander, General Manager, (Labelled Compounds) for extending continuous encouragement for publication of this work. Our sincere thanks to Dr. Vijay Kadwad for providing the magnetic particles and helpful discussions in the early stages of the work.


  1. 1.
    Mackey SE, Creasman WT (1995) J Clin Oncol 13(3):783–793Google Scholar
  2. 2.
    Lavin PT, Knapp RC, Malkasian G, Whitney CW, Bast RC Jr (1987) Obstet Gynacol 69(2):223–227Google Scholar
  3. 3.
    Jacobs I, Bast RC Jr (1989) Hum Reprod 4(1):1–12Google Scholar
  4. 4.
    Kang JO, Hudak WA, Keller N, Criswell BS (1988) Clin Chem 34(10):1983–1986Google Scholar
  5. 5.
    Rustin GJS, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Evans H, Brown S, Oster W (1997) J Clin Oncol 15(1):172–176Google Scholar
  6. 6.
    Christopoulos TK, Diamandis EP (1996) Immunoassay. Academic press, London, pp 227–236CrossRefGoogle Scholar
  7. 7.
    Baker TS, Abbott SR, Daniel SG, Wright JF (1985) Alternative immunoassays. Wiley, UK, pp 59–76Google Scholar
  8. 8.
    Vrinda PC, Paradkar SN, Jyotsna N, Sivaprasad N (2003) J Immunoassay Immunochem 24:285–299CrossRefGoogle Scholar
  9. 9.
    Edwards R (1996) Immunoassays essential data. Wiley, UK, pp 7–12Google Scholar
  10. 10.
    Vrinda PC, Paradkar SN, Nagvekar UH, Samuel G, Sivaprasad N (2005) J Radioanal Nucl chem 266(2):277–283CrossRefGoogle Scholar
  11. 11.
    Kadwad VB (2000) Development of magnetizable immunoadsorbents for radioanalytical separations and measurements. Ph. D. Thesis, University of MumbaiGoogle Scholar
  12. 12.
    Hunter WM, Greenwood FC (1962) Preparation of Iodine-131 labelled human growth hormone of high specific activity. Nature 194:495–496CrossRefGoogle Scholar
  13. 13.
    Chapman RS, Sutherland RM, Ratcliffe JG (1983) Application of 1,1′carbonyldiimiazole as a rapid practical method for the production of solid phase immunoassay reagent. In: Hunter WM, Corrie JET (eds) Immunoassay for clinical chemistry, Churchill Livingstone, Edinburgh, pp 178–190Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2011

Authors and Affiliations

  • Anjani N. Rundekar
    • 1
  • P. C. Vrinda
    • 1
  • N. Sivaprasad
    • 1
  1. 1.Department of Atomic EnergyBoard of Radiation and Isotope Technology (BRIT)Navi MumbaiIndia

Personalised recommendations